72 Hammersmith Road
16 articles with Avillion
Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.
Sanofi, AstraZeneca, Avillion and Diadem recently announced clinical results, providing positive news for patients with multiple myeloma, asthma and Alzheimer’s disease.
PT027, a Novel Fixed-Dose Combination of Albuterol and Budesonide, Used as an As-Needed Rescue Medicine, Significantly Reduced the Risk of a Severe Exacerbation Compared to Albuterol by 27% in Patients With Asthma
Full results from the positive MANDALA Phase III trial showed that PT027 at two different strengths of budesonide, an inhaled corticosteroid, used as an as-needed rescue medicine, demonstrated a statistically significant reduction in the risk of a severe exacerbation versus albuterol rescue in patients with moderate to severe asthma.
Avillion LLP announces the appointment of Dr Anders Gersel Pedersen as a Non-Executive Director of Bond 2 Development 2 GP, the General Partner of Bond Avillion 2, the Avillion entity that enters into the co-development agreements with pharma partners.
Avillion Advances Co-Development Programme With Merck: IND Now Open for Phase II Study of M1095, an Anti-IL-17 A/F Nanobody in Psoriasis
Avillion is focused on this collaborative approach to advancing the development of late-stage clinical candidates for pharmaceutical company partners.
Avillion Announces U.S. Approval of Pfizer's BOSULIF (bosutinib) for the Treatment of Patients With Newly-Diagnosed Ph+ CML
Avillion announces that the FDA today approved a supplemental sNDA for Pfizer's BOSULIF (bosutinib).
Avillion And Pfizer Release: FDA And EMA Accept Regulatory Submissions For BOSULIF® (Bosutinib) For The Treatment Of Patients With Newly Diagnosed Ph+ Chronic Myeloid Leukemia
Merck KGaA, Darmstadt, Germany Advances R&D Strategy Through Unique Development Model With Avillion For Anti IL-17 A/F Nanobody
Avillion Signs Clinical Co-Development Agreement With Merck & Co. To Advance Anti IL-17 A/F Nanobody In Psoriasis
Avillion Release: Company Strengthens Clinical And Regulatory Development Capabilities With The Appointment Of Mark Weinberg As Chief Medical Officer
Pfizer And Avillion Announce Positive Top-Line Results For Phase III BFORE Study Of BOSULIF For First-Line Treatment Of Philadelphia Chromosome Positive Chronic Myeloid Leukemia
Avillion Announces Completion Of Enrolment In Phase III BFORE Trial To Assess BOSULIF (bosutinib) As First-Line Treatment For Patients With Chronic Myelogenous Leukemia
Avillion Announces Dosing Of First Patients In Phase 3 BFORE Trial To Assess BOSULIF® (bosutinib) As First-Line Treatment For Patients With Chronic Myelogenous Leukemia